Navigation Links
Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology

ies in animal models of mucositis, where NU206 was shown to diminish symptoms of mucositis, including diarrhea and weight loss.

Scientists from Nuvelo and Kirin worked together to identify and characterize NU206 as part of a collaboration focused on the discovery of novel, secreted proteins. NU206 is the first compound to enter preclinical studies from this program. Nuvelo signed a collaboration agreement with Kirin in April 2005 to develop NU206. Under the agreement, Nuvelo leads worldwide development, manufacturing and commercialization and all operating expenses and profits related to the development and commercialization of NU206 are shared 60% (Nuvelo)/40% (Kirin).

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic for the treatment of thrombotic-related disorders which is suspended pending review and analysis of clinical data; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short- acting anticoagulant during medical or surgical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rNAPc2 which is in Phase 2 testing for potential use as a cancer therapy, as well as NU206 a preclinical candidate for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at




Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:5/1/2015)... FALLS, N.J. , May 1, 2015 CANTEL ... Andrew A. Krakauer , Chief Executive Officer, will be presenting ... at the Encore at the Wynn in Las ... Thursday, May 14, 2015 at 10:00 AM PT/1:00 PM ET. ... during the day. An audio webcast will ...
(Date:5/1/2015)... , May 1, 2015  Portal Instruments, Inc., ... delivery systems, announced today that Robert Langer, Sc. ... Ph.D., University of Auckland Distinguished Professor have joined the ... to welcome two esteemed biotechnology leaders, Professor Robert ... our team," said Dr. Patrick Anquetil , Chief ...
(Date:5/1/2015)... -- Thoratec Corporation (NASDAQ: THOR ), a world leader in ... hearts, announced today that Marta Antonucci has joined ... This new Europe -based position is ... North America , including Europe , ... , and reports directly to the Chief Executive Officer. Following ...
Breaking Medicine Technology:Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 2Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 3Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 4Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3
... 1, 2011 Milestone Scientific Inc. (OTCQB: MLSS), the ... the Company filed its 2010 year-end results for the ... Securities & Exchange Commission on Wednesday, March 30, 2011. ... teleconference Monday, April 4, 2011 beginning at 4:15 PM ...
... 2011 New data presented today at the 46th ... of the Liver (EASL) demonstrate the antiviral activity of ... both treatment-naive and -experienced patients with chronic genotype-1 (GT1) ... HCV to treat.  Results from SILEN-C1 show a sustained ...
Cached Medicine Technology:Milestone Scientific Will Host Its 2011 Conference Call on Monday, April 4, 2011 2Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 2Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 3Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 4Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 5Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 6
(Date:5/3/2015)... 03, 2015 SpineFrontier, a Less Exposure ... FDA to produce and market their new sacroiliac joint ... used in outpatient settings and is compatible with both ... approach has been extensively researched and refined by SpineFrontier, ... use this approach in conjunction with a sacroiliac joint ...
(Date:5/2/2015)... As one of only 30 Illinois companies ... Health Achievement and Recognition Program (SHARP) certification, Essentra ... the Illinois Department of Labor to host this special ... certification by the Occupational Safety and Health Administration’s (“OSHA”) ... to meet or exceed all of the necessary regulations ...
(Date:5/2/2015)... ” was featured on NewsWatch as part of its monthly ... applications on the market for iOS, Android, and Windows. Joe ... app review and shared with viewers how this app allows ... , In this material world, almost everything is about money. ... is why those things should be prioritized above others. And ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 We are ... The Delray Recovery Center as one of the Top ... known in the addiction treatment field for their ethics ... to innovate and to continue their educational efforts. The ... workplace environment, never forgetting their purpose – to help ...
(Date:5/2/2015)... May 02, 2015 Kare Visits LLC. launched ... for busy caregivers. Kare Visits offers relief for caregivers ... living facilities. According to the Caregiver Action Network, ... average of 20 hours a week caring for an elderly ... cost to hire a nurse, a caregiver is now empowered ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2
... AUGUSTA, Ga. A new strategy that takes advantage of ... extra months of life with few side effects, researchers say., ... a sort of front door by pairing a substance attracted ... be given systemically, said Dr. Sharad Ghamande, Chief of the ...
... BOSTON -- Even yeast understand austerity. A finely tuned system evolved ... times come as fast as they go. The system, a molecular ... protein that turns growth on in times of plenty and shuts ... lab of Wenyi Wei, PhD, an investigator in the Department of ...
... Reporter , THURSDAY, Oct. 27 (HealthDay News) -- Two aspirin a ... half in people who are predisposed to these types of tumors, ... each also cut the risk of other tumors related to Lynch ... to research published in the Oct. 28 online edition of ...
... Reinberg HealthDay Reporter , THURSDAY, Oct. 27 (HealthDay ... part B benefits in 2012 will be less than expected ... U.S. health officials said Thursday. However, for those already ... most people with Medicare have paid a monthly premium of ...
... fourth-generation oncolytic virus designed to both kill cancer cells ... earlier versions when tested in animal models of human ... University Comprehensive Cancer Center Arthur G. James Cancer ... James) are developing the oncolytic virus as a treatment ...
... 27, 2011Bruce Beutler, MD, a co-recipient of the 2011 Nobel ... molecular mechanism that can cause the body to attack itself ... ahead of print in Journal of Interferon & Cytokine ... Inc. ( www.liebertpub.com ) and is available free at ...
Cached Medicine News:Health News:Folate receptors may serve as a front door to ovarian cancer treatment 2Health News:Unraveling the complex signaling that helps cells know when to grow, when to sit tight 2Health News:Unraveling the complex signaling that helps cells know when to grow, when to sit tight 3Health News:Daily Aspirin May Help Prevent Colon Cancer for Those at High Risk 2Health News:Daily Aspirin May Help Prevent Colon Cancer for Those at High Risk 3Health News:Medicare Part B Premium Increase Lower Than Expected 2Health News:New oncolytic virus shows improved effectiveness in preclinical testing 2
... information to facilitate diagnostic accuracy for appropriate ... sterile, disposable device used to inject fluid ... procedures. The device will measure the pressure ... a digital format. The physician can control ...
Maxi-Therm® hyper-hypothermia water blankets from Cincinnati Sub-Zero are designed for single-patient use. These blankets are easy to clean, stain resistant and ideal for isolation cases....
The Neuro-Cool™ System provides pain relief by combining a head wrap with a cold therapy unit for effective migraine treatment....
The ImmunoWELL Borrelia M Test is an enzyme immunoassay (EIA) for the qualitative and/or semiquantitative detection of Borrelia burgdorferi,IgM antibodies in serum and is used as an aid in the diag...
Medicine Products: